Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and oral etoposide alternating maintenance after first-line therapy for advanced epithelial ovarian cancer
ChiCTR2200061780Phase 4Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluzoparib and etoposide in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Progression-free survival. Started Jul 2022; status: recruiting.
02
Drugs
fluzoparibetoposide
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2200061780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061780.